More Articles

Access and Evidence

Calling the Shots?

Katie Osborne, (Dec 10, 2018)

How influential are the value assessments from bodies like ICER?
Access and Evidence

Cutting Out the Middleman

Hugh Gosling, (Dec 7, 2018)

Are PBMs part of the problem or the solution?
Patients and Medical

My Employer Intervened When It Mattered Most

Lucy Fulford, (Dec 5, 2018)

After being diagnosed with breast cancer, Jane Shaw embarked on a propitious treatment regimen. She has her industry to thank for that.
Commercial

Step Aside, Manual Marketing. Automation Is Coming

Adam Chapman, (Dec 4, 2018)

Targeting individual customers is the holy grail of personalization. Automation is the means to get there.
Patients and Medical

The Case For Collaborating With Patient Platforms

Lucy Fulford, (Nov 26, 2018)

In the bid to become pioneers, pharma companies could be missing a trick.
Access and Evidence

Value-Based Contracting: Do We Have The Data?

Andrew Stone, (Nov 20, 2018)

Deals have been signed. Promises have been made. But are companies delivering the goods?
Patients and Medical

An Unlikely Road To Recovery

Lucy Fulford, (Nov 15, 2018)

After being diagnosed with a rare disease, Karen Cheng's life drastically altered course, then the unexpected happened.
Patients and Medical

An Impatient Truth

Paul Simms, (Nov 9, 2018)

How patients taught me that pharma’s partnership efforts simply aren’t enough
Access and Evidence

How To Illustrate Your RWE To Payers

Adam Chapman, (Nov 1, 2018)

Data visualization tools are demystifying real-world evidence.
Patients and Medical

How To Trust In The Age Of (Dis)Information

Lucy Fulford, (Oct 30, 2018)

Amid the smoke and mirrors, pharma has an opportunity to set the record straight.

Pages